Nick Gee
Director & Co-founder @Aboligo
Signup · Get unlimited contacts
WORK HISTORY
Director & Co-founder @Aboligo
Cambridge, GB
AbOliGo (Cambridge UK, founded 2024) is developing a revolutionary platform for rapid, small-scale production of antibody-oligonucleotide conjugates (AOCs), addressing a critical bottleneck in multiplexing. AOCs are transformative tools that combine antibodies\' exquisite targeting specificity with oligonucleotides\' properties - DNA amplification and molecular barcoding, enabling unlimited multiplexing. However, while there are approximately 7 million commercially available antibodies, only ~0.03% are offered as AOCs.Recognizing the growing demand for AOCs, we aim to innovate and re-imagine the manufacturing process through three key technological advancements: Scale - A novel conjugation methodology that enables production at µg scale or mg scale.Quality – Develop new quantitative QC release criteria, guaranteeing batch consistency.Fast – manufacture and deliver AOCs from a large portfolio within days.
EDUCATION
University of Leeds
BSc Biochemistry & Genetics
University of Leeds
PhD Biochemistry, Membrane peptidases
SKILLS
ABOUT NICK GEE
Life Sciences professional with 35 years of experience in R&D and executive roles within the pharmaceutical and biotechnology industries. Founder of the bioconjugation company Innova Biosciences and inventor of Lightning-Link conjugation technology. Expertise spans across:• Antibody conjugation technologies (including dyes, oligos, enzymes, fluorescent proteins, and particles)• Protein purification (including challenging low-abundance targets, both soluble and membrane-bound)• Assay development and high-throughput drug screening• Large-scale gold nanoparticle synthesis• Enzyme characterization/structure determinationProfessional Experience (most recent first):• AbOliGo – Director and Co-founder• Sygnis/Expedeon – Chief Technology Officer (acquired by Abcam)• Innova Biosciences – Founder & CSO/CEO (acquired by Sygnis)• Upstate Biotechnology (now Millipore) – Vice President• Parke-Davis (now Pfizer) – Senior Group Leader• Merck & Co. – Senior Scientist
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.